Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe

Kurt Huber; K. Juhani Airaksinen; Thomas Cuisset; Francisco Marín; Andrea Rubboli; Andrea Rubboli; Gregory Y. H. Lip

doi:10.1160/TH11-08-0602

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(04): 569-571
DOI: 10.1160/TH11-08-0602

Invited Editorial Focus

Schattauer GmbH

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe

Kurt Huber

¹3rd Dept of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria

,

K. Juhani Airaksinen

²Department of Medicine, Turku University Hospital, Turku, Finland

,

Thomas Cuisset

³Department of Cardiology, CHU Timone, Marseille, France

,

Francisco Marín

⁴Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

,

Andrea Rubboli

⁴Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

,

Andrea Rubboli

⁵ivision of Cardiology & Cardiac Catheterization Laboratory, Ospedale Maggiore, Bologna, Italy

,

Gregory Y. H. Lip

⁶University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Rubboli A, Dewilde W, Huber K. et al. The management of patients on oral anticoagulation undergoing coronary stent implantation: a survey among interventional cardiologists from 8 European countries. J Interv Cardiol. 2011 in press
2 Faxon DP, Eikelboom JW, Berger PB. et al. Anti-thrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North-American perspective. Thromb Haemost. 2011; 106: 572-584.
3 Lip G, Huber K, Andreotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
4 Camm AJ, Kirchhof P, Lip GY. et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2501-2555.
5 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
6 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
7 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
8 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
9 Sarafoff N, Sibbing D, Sonntag U. et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost 2010; 104: 626-632.
10 Ruiz-Nodar JM, Marín F, Manzano-Fernández S. et al. An evaluation of the CHADS2stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest 2011; 139: 1402-1409.
11 Hansen ML, Sørensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
12 Steg PG, Huber K, Andreotti F. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
13 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
14 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation 2011; 123: 2362-2372.
15 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
16 Oldgren J, Budaj A, Granger CB. et al. for the REDEEM Investigators. Dabigatran vs. Placebo in patients with acute coronary syndromes on dual anti-platelet therapy:a randomized, double-blind, phase-II trial. Eur Heart J. 2011 epub ahead of print.
17 Alexander JH, Lopes RD, James S. et al. fort he APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 epub ahead of print.
18 O'Riordan M. EXCELLENT results for stopping DAPT at six months, but others say bigger trials are needed. theheart.org [Clinical Conditions > Interventional/Surgery > Interventional/Surgery]; Apr 5, 2011. Accessed at http://www.theheart.org/article/1208053.do on Aug 22, 2011.
19 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106: 739-751.